[1] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383. doi: 10.1016/S2468-1253(18)30056-6
[2] LIANG TJ, BLOCK TM, MCMAHON BJ, et al. Present and future therapies of hepatitis B: From discovery to cure[J]. Hepatology, 2015, 62(6): 1893. doi: 10.1002/hep.28025
[3] PAPATHEODORIDIS GV, CHAN HL, HANSEN BE, et al. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy[J]. J Hepatol, 2015, 62(4): 956. doi: 10.1016/j.jhep.2015.01.002
[4] XIA Y, LIANG TJ. Development of direct-acting antiviral and host-targeting agents for treatment of hepatitis B virus infection[J]. Gastroenterology, 2019, 156(2): 311. doi: 10.1053/j.gastro.2018.07.057
[5] HOSAKA T, SUZUKI F, KOBAYASHI M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection[J]. Hepatology, 2013, 58(1): 98. doi: 10.1002/hep.26180
[6] YAMADA N, MURAYAMA A, SHIINA M, et al. Anti-viral effects of interferon-lambda3 on hepatitis B virus infection in cell culture[J]. Hepatol Res, 2020, 50(3): 283. doi: 10.1111/hepr.13449
[7] ESLAM M, AHLENSTIEL G, GEORGE J. Interferon lambda and liver fibrosis[J]. J Interferon Cytokine Res, 2019, 39(10): 627. doi: 10.1089/jir.2018.0175
[8] HAMMING OJ, TERCZYNSKA-DYLA E, VIEYRES G, et al. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses[J]. EMBO J, 2013, 32(23): 3055. doi: 10.1038/emboj.2013.232
[9] AOKI Y, SUGIYAMA M, MURATA K, et al. Association of serum IFN-lambda3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection[J]. J Gastroenterol, 2015, 50(8): 894. doi: 10.1007/s00535-014-1023-2
[10] WACK A, TERCZYNSKA-DYLA E, HARTMANN R. Guarding the frontiers: the biology of type Ⅲ interferons[J]. Nat Immunol, 2015, 16(8): 802. doi: 10.1038/ni.3212
[11] LIU MQ, ZHOU DJ, WANG X, et al. IFN-lambda3 inhibits HIV infection of macrophages through the JAK-STAT pathway[J]. PLoS One, 2012, 7(4): e35902. doi: 10.1371/journal.pone.0035902
[12] 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志, 2020, 23(1): S9.
[13] PALMA-OCAMPO HK, FLORES-ALONSO JC, VALLEJO-RUIZ V, et al. Interferon lambda inhibits dengue virus replication in epithelial cells[J]. Virol J, 2015, 12: 150. doi: 10.1186/s12985-015-0383-4
[14] MURATA K, ASANO M, MATSUMOTO A, et al. Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection[J]. Gut, 2018, 67(2): 362. doi: 10.1136/gutjnl-2016-312653
[15] POTT J, MAHLAKOIV T, MORDSTEIN M, et al. IFN-lambda determines the intestinal epithelial antiviral host defense[J]. Proc Natl Acad Sci U S A, 2011, 108(19): 7944. doi: 10.1073/pnas.1100552108
[16] WILKINS C, GALE M J. Recognition of viruses by cytoplasmic sensors[J]. Curr Opin Immunol, 2010, 22(1): 41. doi: 10.1016/j.coi.2009.12.003
[17] DING S, KHOURY-HANOLD W, IWASAKI A, et al. Epigenetic reprogramming of the type Ⅲ interferon response potentiates antiviral activity and suppresses tumor growth[J]. PLoS Biol, 2014, 12(1): e1001758. doi: 10.1371/journal.pbio.1001758
[18] MCNAB F, MAYER-BARBER K, SHER A, et al. Type Ⅰ interferons in infectious disease[J]. Nat Rev Immunol, 2015, 15(2): 87.
[19] CHOI J, KIM HJ, LEE J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study[J]. JAMA Oncol, 2019, 5(1): 30. doi: 10.1001/jamaoncol.2018.4070
[20] REHERMANN B, BERTOLETTI A. Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections[J]. Hepatology, 2015, 61(2): 712. doi: 10.1002/hep.27323
[21] XIE Q, ZHOU H, BAI X, et al. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B[J]. Clin Infect Dis, 2014, 59(12): 1714. doi: 10.1093/cid/ciu702
[22] 游佳, 陈靖, 叶巧霞, 等. 聚乙二醇干扰素α加用阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的效果观察[J]. 临床肝胆病杂志, 2016, 32(4): 687.